Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Insulet's flagship product, the Omnipod® Insulin Management System, is a revolutionary tubeless insulin pump that provides continuous insulin delivery with just two parts: a small, waterproof Pod and a handheld Personal Diabetes Manager (PDM) or smartphone app. The company is focused on expanding access to its Omnipod platform, driving innovation in diabetes management, and improving patient outcomes globally.
The Acton headquarters serves as the central hub for Insulet's global operations, including research and development, corporate strategy, marketing, sales, advanced manufacturing, and administrative functions.
The facility is a state-of-the-art building featuring advanced, automated high-speed manufacturing lines for Omnipod products, modern R&D laboratories, and collaborative office spaces designed to foster innovation.
Insulet promotes a patient-centric work culture focused on innovation, collaboration, and a shared mission to improve the lives of individuals with diabetes. The environment encourages agility, problem-solving, and continuous improvement in a fast-paced setting.
The Acton headquarters represents Insulet's commitment to U.S.-based advanced manufacturing, innovation, and scalable growth. It centralizes key functions, enabling efficient operations and capacity to meet increasing global demand for its Omnipod System.
Insulet Corporation has a significant global presence, with direct operations primarily in North America (United States and Canada) and numerous countries across Europe, including the United Kingdom, Germany, France, the Netherlands, and Nordic countries. They also reach additional international markets through a network of distributors. Globally supported functions include sales, marketing, customer care, clinical support, regulatory affairs, and distribution of the Omnipod system to a growing international patient base.
100 Nagog Park
Acton
Massachusetts
USA
Address: 9980 Huennekens St, San Diego, CA 92121, USA (Representative address for Insulet's San Diego presence; specific office details may vary)
Leverages the rich tech talent pool in Southern California to advance Insulet's digital health capabilities and enhance the user experience of its products.
Address: One Dorset Rise, London, EC4Y 8EN, United Kingdom
Drives market expansion and adoption of the Omnipod System in the European region, tailoring strategies to diverse national healthcare systems and patient needs.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Insulet Corporation' leadership includes:
Insulet Corporation has been backed by several prominent investors over the years, including:
Over the past 12 months, Insulet Corporation has seen strategic executive appointments aimed at strengthening its commercial leadership and continued operational excellence, alongside planned retirements and transitions within its senior team.
Discover the tools Insulet Corporation uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Insulet Corporation typically utilizes standard corporate email formats. The most commonly observed and predicted successful format for reaching Insulet employees is the [first_initial][last]@[companydomain].com pattern.
[first_initial][last]@insulet.com
Format
jdoe@insulet.com
Example
75%
Success rate
Insulet Investor Relations | Business Wire • May 9, 2024
Insulet Corporation announced its financial results for the first quarter ended March 31, 2024, reporting a 26% increase in revenue year-over-year. The growth was primarily driven by strong U.S. Omnipod sales, particularly the Omnipod 5 Automated Insulin Delivery System. The company also raised its full-year 2024 guidance for revenue and gross margin....more
Insulet Investor Relations | Business Wire • April 24, 2024
Insulet announced that its Omnipod 5 Automated Insulin Delivery System is now compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems in the United States. This integration offers Omnipod 5 users greater flexibility and choice in managing their diabetes....more
Insulet Investor Relations | Business Wire • February 22, 2024
Insulet Corporation announced robust financial results for the fourth quarter and full year ended December 31, 2023. The company exceeded revenue expectations, driven by the continued strong adoption of Omnipod 5, and provided an optimistic financial outlook for 2024....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Insulet Corporation, are just a search away.